

We claim:

1. Use of a therapeutically effective amount of 3', 4'-anhydrovinblastine, or a pharmaceutically acceptable salt thereof, for the treatment of cancer in a mammal in need of such therapy, wherein said cancer is pancreatic cancer, neuroendocrine cancer or soft tissue sarcoma.
2. The use according to claim 1, wherein said mammal is a human.
3. Use of a therapeutically effective amount of 3', 4'-anhydrovinblastine, or a pharmaceutically acceptable salt thereof, for the treatment of advanced cancer in a mammal in need of such therapy.
4. The use according to claim 3, wherein said mammal is a human.
5. The use according to claim 3 or 4, wherein said advanced cancer is a solid tumor.
6. The use according to claim 3 or 4, wherein said advanced cancer is pancreatic cancer, neuroendocrine cancer, renal cell carcinoma or soft tissue sarcoma.
7. The use according to claim 3 or 4, wherein said advanced cancer is lung cancer, colorectal cancer or breast cancer.
8. The use according to claim 7, wherein said lung cancer is non-small cell lung carcinoma.
9. The use according to claim 3 or 4, wherein said advanced cancer is metastatic cancer.
10. The use according to claim 9, wherein said metastatic cancer is metastatic soft tissue sarcoma or metastatic neuroendocrine cancer.

11. The use according to claim 9, wherein said metastatic cancer is metastatic lung cancer.
12. The use according to claim 11, wherein said metastatic lung cancer is metastatic non-small cell lung carcinoma.
13. The use according to claim 3 or 4, wherein said advanced cancer is a refractory cancer.
14. The use according to claim 13, wherein said refractory cancer is pancreatic cancer, neuroendocrine cancer, renal cell carcinoma or soft tissue sarcoma.
15. The use according to claim 13, wherein said refractory cancer is lung cancer, colorectal cancer or breast cancer.
16. The use according to claim 15, wherein said lung cancer is non-small cell lung carcinoma.
17. The use according to claim 3 or 4, wherein said advanced cancer is an adenocarcinoma.
18. The use according to claim 17, wherein said adenocarcinoma is pancreatic or prostate cancer.
19. The use according to claim 17, wherein said adenocarcinoma is breast or lung cancer.
20. The use according to claim 19, wherein said lung cancer is non-small cell lung carcinoma.

21. Use of a therapeutically effective dose of 3', 4'-anhydrovinblastine for the treatment of cancer in a mammal in need of such therapy, wherein said therapeutically effective dose is between about 2 and about 30 mg of 3', 4'-anhydrovinblastine (AHVB)/m².
22. The use according to claim 21, wherein said dose is between about 10 and about 21 mg AHVB/m².
23. The use according to claim 21 or 22, wherein said mammal is a human.
24. The use according to any one of claims 21, 22 or 23, wherein said cancer is a solid tumor.
25. The use according to any one of claims 21, 22 or 23, wherein said cancer is pancreatic cancer, neuroendocrine cancer, renal cell carcinoma, soft tissue sarcoma, lung cancer, colorectal cancer or breast cancer.
26. The use according to claim 25, wherein said lung cancer is non-small cell lung carcinoma.
27. The use according to any one of claims 21, 22 or 23, wherein said cancer is an advanced cancer.
28. The use according to claim 27, wherein said advanced cancer is a pancreatic cancer, neuroendocrine cancer, renal cell carcinoma, soft tissue sarcoma, lung cancer, colorectal cancer or breast cancer.
29. The use according to claim 28, wherein said lung cancer is non-small cell lung carcinoma.
30. The use according to any one of claims 21, 22 or 23, wherein said cancer is a

metastatic cancer.

31. The use according to claim 30, wherein said metastatic cancer is metastatic soft tissue sarcoma, metastatic neuroendocrine cancer or metastatic lung cancer.
32. The use according to claim 31, wherein said metastatic lung cancer is metastatic non-small cell lung carcinoma.
33. The use according to any one of claims 21, 22 or 23, wherein said cancer is a refractory cancer.
34. The use according to claim 33, wherein said refractory cancer is pancreatic cancer, neuroendocrine cancer, soft tissue sarcoma, lung cancer, colorectal cancer or breast cancer.
35. The use according to claim 34, wherein said lung cancer is non-small cell lung carcinoma.
36. The use according to any one of claims 21, 22 or 23, wherein said cancer is an adenocarcinoma.
37. The use according to claim 36, wherein said adenocarcinoma is pancreatic, prostate cancer, breast or lung cancer.
38. The use according to claim 37, wherein said lung cancer is non-small cell lung carcinoma.
39. Use of 3', 4'-anhydrovinblastine in the manufacture of a medicament for the treatment of pancreatic cancer, neuroendocrine cancer, renal cell carcinoma or soft tissue sarcoma in a mammal.

40. The use according to claim 39, wherein said mammal is a human.
41. Use of 3', 4'-anhydrovinblastine in the manufacture of a medicament for the treatment of advanced cancer in a mammal.
42. The use according to claim 41, wherein said mammal is a human.
43. The use according to claim 41 or 42, wherein said advanced cancer is a solid tumor.
44. The use according to claim 41 or 42, wherein said advanced cancer is pancreatic cancer, neuroendocrine cancer, renal cell carcinoma or soft tissue sarcoma.
45. The use according to claim 41 or 42, wherein said advanced cancer is lung cancer, colorectal cancer or breast cancer.
46. The use according to claim 45, wherein said lung cancer is non-small cell lung carcinoma.
47. The use according to claim 41 or 42, wherein said advanced cancer is metastatic cancer.
48. The use according to claim 47, wherein said metastatic cancer is metastatic soft tissue sarcoma or metastatic neuroendocrine cancer.
49. The use according to claim 47, wherein said metastatic cancer is metastatic lung cancer.
50. The use according to claim 49, wherein said metastatic lung cancer is metastatic non-small cell lung carcinoma.

51. The use according to claim 41 or 42, wherein said advanced cancer is a refractory cancer.
52. The use according to claim 51, wherein said refractory cancer is pancreatic cancer, neuroendocrine cancer, renal cell carcinoma or soft tissue sarcoma.
53. The use according to claim 51, wherein said refractory cancer is lung cancer, colorectal cancer or breast cancer.
54. The use according to claim 53, wherein said lung cancer is non-small cell lung carcinoma.
55. The use according to claim 41 or 42, wherein said advanced cancer is an adenocarcinoma.
56. The use according to claim 55, wherein said adenocarcinoma is pancreatic or prostate cancer.
57. The use according to claim 55, wherein said adenocarcinoma is breast or lung cancer.
58. The use according to claim 57, wherein said lung cancer is non-small cell lung carcinoma.
59. Use of 3', 4'-anhydrovinblastine in the manufacture of a medicament for the treatment of cancer in a mammal, wherein said medicament is formulated for administration at a dose of between about 2 and about 30 mg of 3', 4'-anhydrovinblastine (AHVB)/m².
60. The use according to claim 59, wherein said dose is between about 10 and about 21 mg AHVB/m².

61. The use according to claim 59 or 60, wherein said mammal is a human.
62. The use according to any one of claims 59, 60 or 61, wherein said cancer is a solid tumor.
63. The use according to any one of claims 59, 60 or 61, wherein said cancer is pancreatic cancer, neuroendocrine cancer, renal cell carcinoma, soft tissue sarcoma, lung cancer, colorectal cancer or breast cancer.
64. The use according to claim 63, wherein said lung cancer is non-small cell lung carcinoma.
65. The use according to any one of claims 59, 60 or 61, wherein said cancer is an advanced cancer.
66. The use according to claim 65, wherein said advanced cancer is a pancreatic cancer, neuroendocrine cancer, renal cell carcinoma, soft tissue sarcoma, lung cancer, colorectal cancer or breast cancer.
67. The use according to claim 66, wherein said lung cancer is non-small cell lung carcinoma.
68. The use according to any one of claims 59, 60 or 61, wherein said cancer is a metastatic cancer.
69. The use according to claim 68, wherein said metastatic cancer is metastatic soft tissue sarcoma, metastatic neuroendocrine cancer or metastatic lung cancer.
70. The use according to claim 69, wherein said metastatic lung cancer is metastatic non-small cell lung carcinoma.

71. The use according to any one of claims 59, 60 or 61, wherein said cancer is a refractory cancer.
72. The use according to claim 71, wherein said refractory cancer is pancreatic cancer, neuroendocrine cancer, renal cell carcinoma, soft tissue sarcoma, lung cancer, colorectal cancer or breast cancer.
73. The use according to claim 72, wherein said lung cancer is non-small cell lung carcinoma.
74. The use according to any one of claims 59, 60 or 61, wherein said cancer is an adenocarcinoma.
75. The use according to claim 74, wherein said adenocarcinoma is pancreatic, prostate, breast or lung cancer.
76. The use according to claim 75, wherein said lung cancer is non-small cell lung carcinoma.
77. A pharmaceutical composition comprising 3', 4'- anhydrovinblastine (AHVB) and one or more pharmaceutically acceptable, inert or physiologically active carriers, diluents or adjuvants, said AHVB being formulated for administration to a mammal at a dose of between about 2 and about 30 mg AHVB/m².
78. The pharmaceutical composition according to claim 77, wherein said AHVB is formulated for administration to a mammal at a dose of between about 10 and about 21 mg AHVB/m².
79. The pharmaceutical composition according to claim 78, wherein said mammal is a human.